+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell Viability Assays Market by Product Type, Detection Method, End User, Application - Global Forecast to 2030- Product Image
Cell Viability Assays Market by Product Type, Detection Method, End User, Application - Global Forecast to 2030- Product Image
Sale

Cell Viability Assays Market by Product Type, Detection Method, End User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010770
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cell Viability Assays Market grew from USD 1.99 billion in 2024 to USD 2.22 billion in 2025. It is expected to continue growing at a CAGR of 11.46%, reaching USD 3.82 billion by 2030.

Shaping the Future of Cell Viability Assessment

Cell viability assays underpin the integrity of research across pharmaceuticals, biotechnology and diagnostics, offering vital insights into cellular health, proliferation and response to external stimuli. As laboratories worldwide intensify efforts in drug discovery, toxicity screening and basic biological research, reliable viability data has become indispensable for decision makers seeking to accelerate timelines while maintaining rigorous quality standards.

Evolving demands in precision medicine and personalized therapies have elevated the role of high-throughput viability platforms that deliver rapid, reproducible results. Advances in assay chemistry, coupled with integrated data management tools, are reshaping workflows and enabling seamless collaboration between scientists, clinicians and regulatory authorities.

This executive summary distills key developments, segmentation insights and regional dynamics shaping the global cell viability assays market. By examining transformative trends, tariff implications and competitive strategies, we offer an authoritative foundation for stakeholders aiming to harness emerging opportunities and navigate potential challenges effectively.

Emerging Forces Redefining Cell Viability Technologies

The landscape of cell viability technologies is undergoing a radical transformation driven by innovations in detection chemistry and automation. Label-free and real-time monitoring techniques now complement traditional endpoint assays, empowering researchers with continuous data streams that enhance experimental fidelity and decision-making agility.

Integration of microfluidics platforms with viability assays has facilitated miniaturization and multiplexed analyses, reducing reagent consumption while scaling throughput. Meanwhile, artificial intelligence and machine learning algorithms are infusing data analytics with predictive modeling capabilities, enabling early identification of cellular responses and toxicity markers.

Concurrently, sustainability considerations are prompting the adoption of eco-friendly assay reagents and recyclable consumables. This shift underscores a broader industry commitment to reducing environmental impact without compromising analytical performance. Altogether, these forces are propelling a new era of precision, efficiency and environmental responsibility in cell viability testing.

Assessing the Ripple Effects of 2025 US Tariffs on Cell Viability Tools

The implementation of new United States tariffs in 2025 has introduced a complex set of cost pressures for suppliers and end users of cell viability assays. Increased import duties on critical reagents, instruments and detection kits have driven up procurement budgets, compelling laboratories to reassess sourcing strategies and contract negotiations.

In response, many organizations are exploring local manufacturing partnerships to mitigate tariff exposure and ensure continuity of supply. This shift has spurred investments in regional production facilities and logistics networks that streamline distribution while preserving product quality. Simultaneously, some vendors are absorbing a portion of tariff-related costs to maintain price stability for key customers, betting on long-term loyalty and volume commitments.

While these adaptive strategies have softened immediate financial impacts, continued monitoring of trade policies remains essential. Stakeholders must remain vigilant to anticipate potential new duties or trade agreements that could further influence cost structures and competitive positioning.

Illuminating Insights from Market Segmentation

A nuanced understanding of market segmentation reveals how distinct product categories, detection methodologies, end-user groups and applications converge to shape demand. By product type, the market encompasses assay kits, instruments and software, with assay kits further differentiated by colorimetric, fluorometric and luminescent options that cater to varied sensitivity and throughput requirements. In the realm of detection, chemiluminescent and colorimetric methods coexist alongside fluorometric and luminescent approaches, the former refined into Calcein AM and Resazurin formats and the latter built upon ATP and Luciferase systems.

Demand emanates from a spectrum of end users, including academic and research institutions that drive basic science innovation, contract research organizations executing outsourced studies, and hospitals with diagnostic centers focused on clinical applications. Pharmaceutical and biotechnology companies rely on viability assays throughout drug development pipelines, from target identification to preclinical safety assessments. Application-wise, fundamental research efforts leverage viability measurements to elucidate cellular mechanisms, while cell proliferation studies, cytotoxicity testing and drug screening each impose distinct performance criteria, such as assay speed, sensitivity and compatibility with high-content imaging platforms.

By weaving these segmentation layers together, stakeholders can identify high-growth niches and tailor product offerings to address the precise needs of each customer cohort.

Regional Dynamics Driving Growth in Cell Viability Testing

Regional dynamics are driving diverse growth trajectories in the global cell viability assays market. In the Americas, robust investment in life sciences infrastructure and a concentration of leading pharmaceutical research hubs underpin steady demand for advanced viability platforms. This region benefits from well-established distribution channels and collaborative alliances between academia and industry, fostering rapid adoption of novel assay formats.

Meanwhile, Europe, the Middle East & Africa exhibit heterogeneous growth patterns shaped by varying regulatory frameworks and funding landscapes. Western Europe leads with strong R&D funding and a collaborative regulatory environment, whereas emerging markets in Eastern Europe, the Gulf region and Africa are witnessing increased public-private partnerships aimed at upgrading research facilities and diagnostic capabilities.

Meanwhile, Asia-Pacific has emerged as a hotbed of activity, driven by expanding research budgets in China, India and Southeast Asia. Government initiatives targeting biotechnology development and enhanced healthcare infrastructure investments are propelling demand for cost-effective, high-throughput viability assays. Local manufacturers are rising to the challenge by developing regionally tailored solutions and forging global distribution alliances to capture growing market share.

Strategic Profiles of Leading Cell Viability Innovators

Competitive intensity within the cell viability assays arena continues to escalate as key players pursue innovation through strategic collaborations and portfolio expansion. Leading assay kit manufacturers are introducing next-generation reagent formulations that combine enhanced sensitivity with reduced cytotoxicity, positioning themselves to capture high-content screening applications. Instrument suppliers are embedding multiplexing capabilities and real-time monitoring features directly into benchtop systems, thus simplifying workflows and differentiating their product offerings.

Software providers are intensifying efforts to integrate viability data with broader bioinformatics platforms, offering seamless data aggregation, analysis and visualization across multi-omics datasets. This convergence of hardware, chemistry and software is fueling partnerships and acquisition activity, as end-to-end solutions gain favor among large research institutions and contract organizations seeking operational efficiency.

Emerging players focusing on niche assay formats or geographic expansions are also reshaping the competitive field. By tailoring product lines to specific regional preferences and regulatory requirements, these innovators are carving out defensible market segments, forcing incumbents to reexamine pricing structures and service models. Overall, the competitive landscape favors those who deliver holistic, interoperable solutions that address both current experimental demands and future growth imperatives.

Navigating Success with Strategic Recommendations

To secure a competitive edge, industry leaders should prioritize investment in automation and digital integration that streamline assay workflows from sample preparation to data interpretation. Embracing modular, scalable platforms will enable laboratories to adapt rapidly to evolving throughput demands and minimize downtime associated with reconfiguration.

Supply chain diversification remains paramount in mitigating risks tied to trade policies and geopolitical uncertainties. Cultivating relationships with regional manufacturers and alternative suppliers will bolster resilience and ensure uninterrupted access to critical reagents and instruments. Concurrently, fostering co-development partnerships with academic centers can accelerate the translation of cutting-edge chemistries and detection methods into commercially viable products.

Finally, leaders must strengthen their value proposition through comprehensive service offerings, including robust training programs, flexible financing models and advanced data analytics support. By delivering not only high-performance assays but also consultative expertise, organizations can deepen customer engagement, increase loyalty and capture a greater share of the growing market.

Rigorous Research Methodology Ensuring Reliable Insights

Our analysis draws on a rigorous multi-stage research approach, beginning with an exhaustive review of published literature, patent filings and regulatory submissions to map the current technological landscape. This secondary research was complemented by primary interviews with executives, product managers and end users across academia, contract research organizations and industry to validate key trends and identify unmet needs.

Quantitative data was systematically triangulated against public financial reports and proprietary shipment data to ensure consistency and accuracy. We applied advanced statistical techniques to discern growth patterns across segmentation layers and regions, while sensitivity analyses assessed the robustness of our insights under varying market conditions.

Throughout the process, we engaged an advisory panel of subject matter experts in cell biology and assay development to peer-review findings and provide critical feedback. This structured methodology underpins the credibility of our conclusions and equips stakeholders with a transparent, defensible foundation for strategic decision making.

Consolidating Key Takeaways for Decision Makers

In sum, the global cell viability assays market is poised for sustained evolution driven by technological innovation, shifting trade dynamics and expanding regional capacity. Stakeholders equipped with a clear understanding of segmentation intricacies, competitive strategies and regional growth drivers will be best positioned to capitalize on emerging opportunities.

Navigating this complex landscape requires agile supply chain strategies, thoughtful investment in integrated solutions and collaboration with research institutions to stay ahead of the curve. By synthesizing the insights presented here, decision makers can chart a course toward enhanced operational efficiency, differentiated product offerings and long-term market leadership.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Assay Kits
      • Colorimetric Kits
      • Fluorometric Kits
      • Luminescent Kits
    • Instruments
    • Software
  • Detection Method
    • Chemiluminescent
    • Colorimetric
    • Fluorometric
      • Calcein AM
      • Resazurin
    • Luminescent
      • ATP
      • Luciferase
  • End User
    • Academic And Research Institutions
    • Contract Research Organizations
    • Hospitals And Diagnostic Centers
    • Pharmaceutical And Biotechnology Companies
  • Application
    • Basic Research
    • Cell Proliferation Studies
    • Cytotoxicity Testing
    • Drug Screening
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Promega Corporation
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Corning Incorporated
  • Lonza Group AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cell Viability Assays Market, by Product Type
8.1. Introduction
8.2. Assay Kits
8.2.1. Colorimetric Kits
8.2.2. Fluorometric Kits
8.2.3. Luminescent Kits
8.3. Instruments
8.4. Software
9. Cell Viability Assays Market, by Detection Method
9.1. Introduction
9.2. Chemiluminescent
9.3. Colorimetric
9.4. Fluorometric
9.4.1. Calcein AM
9.4.2. Resazurin
9.5. Luminescent
9.5.1. ATP
9.5.2. Luciferase
10. Cell Viability Assays Market, by End User
10.1. Introduction
10.2. Academic And Research Institutions
10.3. Contract Research Organizations
10.4. Hospitals And Diagnostic Centers
10.5. Pharmaceutical And Biotechnology Companies
11. Cell Viability Assays Market, by Application
11.1. Introduction
11.2. Basic Research
11.3. Cell Proliferation Studies
11.4. Cytotoxicity Testing
11.5. Drug Screening
12. Americas Cell Viability Assays Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cell Viability Assays Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cell Viability Assays Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Merck KGaA
15.3.3. Bio-Rad Laboratories, Inc.
15.3.4. Promega Corporation
15.3.5. PerkinElmer, Inc.
15.3.6. Agilent Technologies, Inc.
15.3.7. Danaher Corporation
15.3.8. Becton, Dickinson and Company
15.3.9. Corning Incorporated
15.3.10. Lonza Group AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CELL VIABILITY ASSAYS MARKET MULTI-CURRENCY
FIGURE 2. CELL VIABILITY ASSAYS MARKET MULTI-LANGUAGE
FIGURE 3. CELL VIABILITY ASSAYS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CELL VIABILITY ASSAYS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CELL VIABILITY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CELL VIABILITY ASSAYS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CHEMILUMINESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CALCEIN AM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY RESAZURIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ATP, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUCIFERASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CELL PROLIFERATION STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CYTOTOXICITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 53. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 54. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 55. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 56. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 61. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 98. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 99. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 103. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 104. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 105. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 106. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 117. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 118. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 119. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 120. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 124. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 125. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 126. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 127. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 152. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 153. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 154. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 155. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 166. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 167. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 168. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 169. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 174. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 175. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 176. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 194. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 195. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 196. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 197. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 201. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 202. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 203. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 204. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 216. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 217. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 218. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 222. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 223. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 224. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 225. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 242. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 244. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 245. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 246. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 247. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 251. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 252. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 253. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 254. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 257. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 258. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 259. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 260. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 261. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 286. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 287. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 288. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 289. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. CELL VIABILITY ASSAYS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 327. CELL VIABILITY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cell Viability Assays market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Promega Corporation
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Corning Incorporated
  • Lonza Group AG

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.82 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cell Viability Assays - Global Strategic Business Report - Product Image

Cell Viability Assays - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Cell Viability Assays Market Report 2025 - Product Image

Cell Viability Assays Market Report 2025

  • Report
  • 200 Pages
  • Global
From
2024 Global Forecast for Cell Viability Assays Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Cell Viability Assays Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Glycated Albumin Assay Market by Product Type, Method, End User, Application - Global Forecast to 2030 - Product Image

Glycated Albumin Assay Market by Product Type, Method, End User, Application - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
GST Assay Kit Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

GST Assay Kit Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Cell Viability Assay Market

The Cell Viability Assay market is a segment of the Laboratory Testing industry that focuses on the measurement of the number of viable cells in a sample. This type of assay is used to assess the health of cells, as well as to determine the effectiveness of treatments such as drugs or radiation. Cell viability assays are used in a variety of research and clinical applications, including cancer research, stem cell research, and drug development. Cell viability assays are typically performed using a variety of techniques, such as flow cytometry, fluorescent microscopy, and colorimetric assays. These assays are used to measure the number of viable cells in a sample, as well as to assess the health of the cells. Some of the companies in the Cell Viability Assay market include Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Promega Corporation, and Agilent Technologies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.